AtriCure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AtriCure, Inc. (NASDAQ: ATRC) on June 15, 2021. The report discloses corporate governance changes effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The Board of Directors elected two new independent directors effective June 15, 2021:
- Deborah H. Telman: Elected as a Director and appointed to the Nominating and Corporate Governance Committee. She currently serves as General Counsel of Organon & Co. and previously held senior legal roles at Sorrento Therapeutics, Johnson Controls, Abbott Laboratories, and The Boeing Company.
- Maggie Yuen: Elected as a Director and appointed to the Audit Committee. She currently serves as Chief Financial Officer of Penumbra, Inc. and previously held finance leadership roles at Thermo Fisher Scientific, Mirion Technologies, Boston Scientific, and Johnson & Johnson.
Both directors will receive compensation in accordance with the Company's policies for non-employee directors. No transactions requiring disclosure under Item 404(a) of Regulation S-K exist between the Company and the new directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the independence status of Ms. Telman and Ms. Yuen against NASDAQ listing standards.
- Review the Company's 2021 Proxy Statement for details on director compensation policies.
- Confirm the specific committee assignments: Ms. Telman (Nominating and Corporate Governance) and Ms. Yuen (Audit).
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.